Novartis, Takeda See Industry Better Prepared For Next Pandemic
Repurposing Drugs Not Ideal
Novartis and Takeda’s R&D efforts saw an impact from the COVID-19 pandemic, but both Lutz Hegemann and Andrew Plump believe that when the next pandemic hits, the industry and regulators will be better prepared for it.
